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Gasdermin D in peripheral myeloid cells drives
neuroinflammation in experimental autoimmune
encephalomyelitis
Sheng Li1*, Yuqing Wu1*, Dongxue Yang1, Chunyan Wu1, Chunmei Ma1, Xue Liu1, Paul N. Moynagh2,3, Bingwei Wang4, Gang Hu4, and Shuo Yang1
The NLRP3 inflammasome is critical for EAE pathogenesis; however, the role of gasdermin D (GSDMD), a newly identified
pyroptosis executioner downstream of NLRP3 inflammasome, in EAE has not been well defined. Here, we observed that the
levels of GSDMD protein were greatly enhanced in the CNS of EAE mice, especially near the areas surrounding blood vessels.
GSDMD was required for the pathogenesis of EAE, and GSDMD deficiency in peripheral myeloid cells impaired the infiltration
of immune cells into the CNS, leading to the suppression of neuroinflammation and demyelination. Furthermore, the loss of
GSDMD reduced the activation and differentiation of T cell in the secondary lymphoid organs and prevented T cell infiltration
into CNS of EAE. The administration of inflammasome-related cytokines partially rescued the impairment of pathogenesis of
EAE in GSDMD KO mice. Collectively, these findings provide the first demonstration of GSDMD in peripheral myeloid cells
driving neuroinflammation during EAE pathogenesis.
Introduction
Multiple sclerosis (MS) is an incurable and progressive
inflammatory disease of the central nervous system (CNS) with
neuropathological features, including inflammatory demyelina-
tion, chronic axonal damage, and neurodegeneration (Frohman
et al., 2006). However, the etiology of MS is not well understood,
with the underlying basis to pathogenesis being ill-defined.
Experimental autoimmune encephalomyelitis (EAE) is the
most commonly used animal model for studying MS since it
shares neuropathological features with MS and can help to de-
fine the contribution of immune events to the development of
MS (Ransohoff, 2012). EAE is mediated by myelin-specific
T cells, which are activated in the peripheral lymphoid organs
and then migrate into CNS by crossing the blood–brain barrier
to mediate inflammatory responses, resulting in demyelination
and neurodegeneration (Stromnes et al., 2008).Moreover, much
evidence suggests that innate immune cells play critical roles
during the process of EAE. Myeloid cells, such as dendritic cells
(DCs) and macrophages, serve as APCs that mediate the cellular
immune response by processing and presenting myelin antigens
for recognition by T cells (Heppner et al., 2005; Chastain et al.,
2011). Additionally, myeloid cells produce cytokines and che-
mokines that respectively facilitate the activation and differen-
tiation of naive CD4+ T cells toward T helper type 1 (Th1) and
Th17 cell lineages, and the translocation of effector T cells into
CNS, all of which contributes to the progression of EAE. Fur-
thermore, the peripheral myeloid cells themselves can be re-
cruited into CNS and together with CNS-resident innate
immune cells, such as microglia and astrocyte, facilitate neu-
roinflammation to cause neuron damage in EAE (Greter et al.,
2005; Goverman, 2009; Chastain et al., 2011; Duffy et al., 2014).
Inflammasomes are cytosolic multiprotein complexes that
are vital players of innate immunity and especially in the initi-
ation of inflammatory responses in myeloid cells (Martinon
et al., 2002). Upon recognition of stimuli, inflammasome-
associated sensor proteins, together with apoptosis-associated
speck-like protein containing CARD (ASC) and pro-inflammatory
cysteinyl aspartate–specific proteinase (caspases; caspase-
1 and -11), assemble into an oligomeric complex leading to cas-
pase autoactivation, which controls the cleavage of pro–IL-1β and
pro–IL-18 precursors into their mature forms and also induces a
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type of proinflammatory programmed cell death termed py-
roptosis (Rathinam et al., 2012; Latz et al., 2013; Jorgensen and
Miao, 2015). Notably, several independent studies showed that
the expression of caspase-1, IL-1β, and IL-18 is elevated in the
peripheral blood mononuclear cells and serum of MS patients
(Huang et al., 2004). Furthermore, increasing recent evidence
indicate that the NOD-like receptor protein 3 (NLRP3) in-
flammasome in APCs plays a critical role in the pathogenesis
of EAE model by mediating chemotactic immune cell recruit-
ment to the CNS (Gris et al., 2010; Inoue et al., 2012). Addi-
tionally, a recent study reported that Th17 cell–intrinsic ASC
can promote the process of EAE by inducing IL-1β production
via ASC–NLRP3–caspase-8 inflammasome axis (Martin et al.,
2016). These studies highlight an important role for in-
flammasome in MS and EAE pathogenicity.
Gasdermin D (GSDMD) is a recently identified pore-forming
protein, which mediates pyroptosis (Kayagaki et al., 2015; Shi
et al., 2015). Proinflammatory caspases (caspase-1 and -4/5 in
humans and caspase-1 and -11 in mice) can cleave GSDMD at its
central linker domain, thereby releasing the autoinhibition by
C-terminal GSDMD domain on the N-terminal GSDMD domain,
causing N-terminal GSDMD domain fragments to translocate to
the plasma membrane, where they oligomerize to form mem-
brane pores, leading to lytic cell death or the secretion of pro-
cessed IL-1β and IL-18 in living cells through pores (Ding et al.,
2016; Liu et al., 2016; Evavold et al., 2018). Recent studies
demonstrate that GSDMD plays a critical role in septic shock in
response to bacterial infection, and in inflammasome-driven
autoinflammatory diseases such as familial Mediterranean fe-
ver and neonatal-onset multisystem inflammatory disease
(Kanneganti et al., 2018; Xiao et al., 2018). Interestingly, a recent
study reported that GSDMD accumulation was observed in mi-
croglia and oligodendrocytes of CNS in both MS and EAE
(McKenzie et al., 2018). However, to date there have been no
reports on a pathophysiological role for GSDMD in neuro-
inflammation or EAE pathogenesis.
We now provide the first insight into the physiological
function of GSDMD in EAE pathogenesis and describe the reg-
ulatory mechanism of GSDMD-mediated pyroptosis in the de-
velopment of neuroinflammation during EAE. We discover that
myeloid cell–intrinsic GSDMD is crucial for EAE pathogenesis by
mediating the activation and differentiation of T cells in the
secondary lymphoid organs, which facilitates T cell–mediated
neuroinflammation and demyelination in the CNS.
Results
GSDMD-mediated pyroptosis is activated in the CNS of EAE
To investigate whether GSDMD contributes to the pathogenesis
in MS disease, we first tested the level of its expression in CNS,
spleen, and LNs of an EAE mice model, which was induced
by administration of myelin oligodendrocyte glycoprotein
(MOG35–55) peptide and pertussis toxin. Immunoblotting
analysis demonstrated greatly increased expression and cleav-
age of GSDMD and caspase-1/11 in the CNS and peripheral
lymphoid organs of EAE-induced mice at the peak stage relative
to untreated mice (Fig. 1 A and Fig. S1 A), suggesting that the
pyroptosis mediated by GSDMD is indeed involved in the dis-
ease. Immunohistochemical analysis further confirmed the
high-level expression of GSDMD in EAE CNS, and it was espe-
cially concentrated in lesion areas of spinal cord that were also
characterized by strong cell infiltration. Interestingly, the posi-
tive staining of GSDMD was barely detectable in the CNS
of control mice (Fig. 1 B). In addition, most of the cells highly
expressing GSDMD and caspase-11 were detected in close
proximity to the expanded capillaries at the edge of lesions in the
spinal cord, as evidenced by closely adjacent expression of the
endothelial marker CD31 (Fig. 1 C and Fig. S1 B), suggesting that
these GSDMD-positive cells may represent cells recruited from
the periphery. Moreover, FACS revealed a marked increase of
caspase-1/11+ propidium iodide (PI)+ cells gated on the CD11b+
Ly6C+ (infiltrated peripheral monocytes/macrophages) in the
CNS of mice during EAE compared with control mice (Fig. 1 D).
Collectively, these data suggest that GSDMD-mediated py-
roptosis is associated with EAE development, and its activation
in CNS may be derived from infiltrating peripheral cells.
GSDMD is essential for EAE induction
To directly evaluate the requirement of GSDMD for EAE pro-
gression, we compared EAE in GSDMD KO mice and WT mice.
We found that GSDMD−/− mice were more resistant to EAE and
developed less severe disease and clinical scores compared with
WT mice (Fig. 2 A). Histopathological analysis (H&E staining
and Luxol fast blue [LFB] staining) showed fewer infiltrating
inflammatory cells and less demyelination in the spinal cord of
GSDMD−/− mice relative to their WT counterparts (Fig. 2 B).
Myelin basic protein (MBP) is a protein that contributes to the
process of myelination of nerves and maintenance of neural
structure and is also as a marker of the myelin sheath of oligo-
dendrocytes, with its loss being a major pathological feature of
MS (Bradl and Lassmann, 2010). Immunofluorescence analysis
showed regions of considerable diminution MBP expression at
the peak of EAE disease inWTmice, but these were not apparent
in GSDMD−/− mice (Fig. 2 C). Moreover, GSDMD−/− mice had
significantly reduced numbers of activated macrophages, mi-
croglia, and astrocytes in EAE spinal cord compared with WT
mice as determined by expression of the microglial and astro-
cyte cell markers, ionized calcium-binding adapter molecule
1 (IBA1), and glial fibrillary acidic protein (GFAP), respectively
(Fig. S1, C and D). This indicates that GSDMD deficiency is as-
sociated with less severe neuroinflammation in EAE. Further-
more, fewer CD4+ T cells were detected at the edge of spinal
cords of GSDMD−/− mice relative to WT counterparts, further
suggesting the impairment of recruitment of immune cells in
GSDMD−/− mice during EAE (Fig. 2 D). Consistent with im-
munostaining analysis, FACS revealed a marked reduction of
T cells (CD45+, CD4+, and CD8+), myeloid cells, and activated
microglia cells (CD45+, CD11b+) in the CNS of GSDMD−/− mice
during EAE compared with WT mice (Fig. 2, E and F). With
respect to the population of CNS infiltrating CD4+ T cells, the
percentages and absolute numbers of both Th1 and Th17 cells
were greatly reduced in GSDMD−/− mice (Fig. 2, G and H). Al-
together, these data suggest that GSDMD is essential for EAE
pathogenesis.
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Figure 1. GSDMD is strongly expressed and processed in CNS during EAE. (A) Immunoblot analysis of full-length (FL) and cleaved GSDMD, caspase-11 and
caspase-1 in the spinal cords and spleen (SP) from three pairs of control (CTRL) or EAE-induced WT mice at day 18 after immunization. (B) Immunohisto-
chemistry images showing GSDMD expression in the spinal cord of control or EAE-induced WT mice at day 18 after immunization. Scale bar, 100 µm.
(C) Immunofluorescent labeling of CD31 (green), GSDMD (red), and DAPI (blue) demonstrates the angiogenesis and the distribution of GSDMD (indicated by
arrows) in the lesion area of spinal cord of EAE-induced WT mice at day 18 after immunization. Scale bar, 100 µm. (D) Flow-cytometric analysis of caspase-1/
11+PI+ cells from CD11b+ Ly6C+ cells infiltrated to the spinal cord and brain of CTRL and MOG35-55-immunizedWTmice at day 18 after immunization (n = 3 mice
per group). Data are presented as a representative plot (left) and quantified percentages (right). Data are representative of three independent experiments. ***,
P < 0.001. Error bars show means ± SEM. Unpaired t test for D.
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Figure 2. GSDMD-deficient mice are resistant to EAE pathogenesis and neuroinflammation. (A) Mean clinical scores of age-matched female WT and
GSDMD−/−mice subjected toMOG35-55-induced EAE (n = 10mice per group); immunoblot analysis of GSDMD expression in spleen from indicated mice. (B)H&E
staining and LFB staining of spinal cord sections from EAE-induced WT and GSDMD−/− mice showing inflammatory cell infiltration and demyelination,
respectively (arrowheads). Scale bar, 500 µm. (C) Immunofluorescent labeling of MBP (red) and DAPI (blue) visualizing the impairment of myelination
(arrowheads) of EAE-induced WT and GSDMD−/− mice, respectively. Scale bar, 100 µm. (D) Immunohistochemistry analysis for infiltrating CD4+ T cells in the
spinal cord of EAE-induced WT and GSDMD−/− mice (representative images on left and quantified cell numbers on right, n = 3 mice per group), respectively.
Scale bar, 100 µm. (E and F) Flow-cytometric analysis of immune cells (including CD45+CD4+ T cells, CD45+CD8+ T cells, and CD45+CD11b+ monocytes)
infiltrated to the spinal cord and brain of MOG35-55-immunized WT and GSDMD−/− mice at day 18 after immunization (n = 7 for WTs, n = 8 for GSDMD−/− mice).
Data are presented as a representative plot (E) and summary graph of the absolute cell numbers (F). (G and H) Flow-cytometric analysis of Th1 (IFN-γ+) and
Th17 (IL-17A+) cells from CD4+ T cells infiltrated to the spinal cord and brain of MOG35-55-immunized WT and GSDMD−/− mice at day 18 after immunization (n = 7
mice per group). Data are presented as a representative plot (G), quantified percentage, and absolute cell numbers (H). Data are pooled from three independent
experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001. Error bars show means ± SEM. Unpaired t test for A, D, and H, and multiple unpaired t test for F.
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GSDMD deficiency in peripheral myeloid cells suppresses
neuroinflammation and pathogenesis of EAE
To determine whether GSDMD deficiency in peripheral cells or
CNS-resident cells contributes to the suppression of EAE, we
measured the expression of GSDMD in various tissues, but it was
strikingly low in CNS of homeostatic state (Fig. 3 A). Moreover,
compared with peripheral cells (including bone marrow–
derived macrophages [BMDMs], bone marrow–derived DCs, and
T cells), microglia displayed very low expression of GSDMDwith
barely detectable expression other CNS cells including as-
trocytes, oligodendrocyte progenitor cells, and neurons (Fig. 3
B). Next, we generated bone marrow chimeric mice by adop-
tively transferringWT bonemarrow cells into lethally irradiated
WT or GSDMD−/− recipient mice. Comparable EAE clinical scores
were observed between these two recipients (Fig. 3 C), which
also had comparable levels of infiltrated immune cells in the
CNS (Fig. 3 C). However, a reverse bone marrow transfer ex-
periment in which lethally irradiated WT recipient mice were
reconstituted with bone marrow cells isolated from WT or
GSDMD−/− mice showed that WT mice reconstituted with the
GSDMD deficiency bone marrow were more refractory to EAE
induction than WT donors (Fig. 3 D). Additionally, the recruit-
ment of peripheral immune cells into the CNS was reduced in
GSDMD−/− donors compared with WT donors (Fig. 3, D and E).
H&E and LFB (Fig. 3 F) staining also confirmed that fewer in-
filtrating inflammatory cells and decreased demyelination were
apparent in the spinal cord of GSDMD−/− donor mice. Notably,
the CNS ofWT recipients reconstituted with the GSDMD−/− bone
marrow had significantly decreased expression of several in-
flammatory chemokines and cytokines known to mediate im-
mune cells recruitment and neuroinflammation after the
induction of EAE (Fig. 3 G). Thus, these results suggest that
GSDMD functions in peripheral cells to promote EAE patho-
genesis in the CNS.
We next examined if this role for GSDMD in peripheral cells
was intrinsic to peripheral T cells by crossing the GSDMDfl/fl
mice with CD4-Cre mice to generate T cell conditional GSDMD
KO mice. GSDMDfl/flCD4-Cre and littermate control GSDMDfl/fl
mice developed similar clinical symptoms and immune cells
infiltration after immunization (Fig. S2 and Fig. 3, H and J),
suggesting that GSDMD in T cells has no role in driving EAE-
associated pathogenesis. However, peripheral myeloid cells (DCs
andmacrophages) and CNS-resident microglia also contribute to
neuroinflammation and pathogenesis in EAE (Duffy et al., 2014).
To further explore the potential contribution of GSDMD in mi-
croglia to EAE pathogenesis, we crossed GSDMDfl/fl mice with
Cx3cr1-CreERT2 mice to generate microglia conditional GSDMD
KO mice. Tamoxifen was administered to these mice to specif-
ically delete GSDMD in microglia. This experimental design is
based on a previous report showing that short-lived blood
monocytes are renewed within 6 wk after tamoxifen adminis-
tration, whereas GSDMD is specifically deleted in long-lived
microglia of GSDMDfl/flCx3cr1-CreERT2 mice (Yona et al., 2013).
GSDMD deficiency in microglia had no effect on the EAE phe-
notype (Fig. 3, I and J), and this is consistent with the bone
marrow transfer experiments that concluded a lack of role for
GSDMD in CNS resident cells. Together, these data demonstrate
that deletion of GSDMD in peripheral myeloid cells might be
responsible for the suppression of the pathogenesis and neuro-
inflammation of EAE.
GSDMD deficiency impairs the priming and differentiation of
T cell by myeloid cells and increases T cell accumulation in
peripheral lymphoid organs during EAE
Antigen-activated T cells are key effector cells in the patho-
genesis of EAE, which undergo activation in secondary lymphoid
organs and thenmigrate into CNS due to the actions of cytokines
and chemokines produced by APCs (Goverman, 2009). Given the
phenotype observed above, we hypothesized that GSDMD in
peripheral myeloid cells may be important for T cell response in
peripheral lymphoid organs during EAE. Thus, decreased infil-
tration of CD4+ T cells in the CNS of GSDMD−/− mice may be
caused by decreased cellularity in the periphery. Unexpectedly,
GSDMD-deficient mice show enlargement of spleen and drain-
ing LNs (DLNs) at the peak stage of EAE (Fig. 4, A and B), in-
dicating the potential accumulation of T cells in peripheral
lymphoid organs after immunization. Most notably, while the
absolute numbers of CD4+ T cells (Fig. 4 C) were increased in
the secondary lymphoid organs of GSDMD−/− mice after EAE, the
percentages of Th1 and Th17 cells were reduced, but their
numbers were comparable in WT and GSDMD−/− mice (Fig. 4, D
and E). We next analyzed the naive CD62+CD44−CD4+ T cells
(Th0) that have not been activated by APCs during EAE. Inter-
estingly, the numbers of naive T cell in spleen and LNs were
much higher in GSDMD−/− mice after EAE than WT mice (Fig. 4,
D and F), which might be responsible for the observed increase
of CD4+ T cells in the secondary lymphoid organs of GSDMD−/−
mice. Given that we observed significantly reduced percentages
of Th1 and Th17 cells in the secondary lymphoid organs of
GSDMD−/− mice during EAE, we suggest that GSDMD plays an
important role in regulating T cell priming and differentiation in
the peripheral lymphoid organs during EAE. This was directly
addressed by performing in vitro T cell proliferation and dif-
ferentiation assays that revealed GSDMD−/− DCs to be greatly
impaired in driving EAE MOG-induced T cell activation and
differentiation relative to WT DCs (Fig. 4, G–I). Since the num-
ber of Th1 and Th17 cells in the secondary lymphoid organs was
unaltered in GSDMD−/− mice after EAE and the infiltration of Th1
and Th17 cells in the CNS was decreased (Fig. 2, G and H), we
speculate that GSDMD deficiency also affects T cell migration
into CNS. Additionally, we evaluated the profiles of T cells in
thymus, spleen, and LN of GSDMD−/− mice in homeostatic state.
There were no significant differences observed betweenWT and
GSDMD−/− mice in the development of T cells and the profiles of
naive T cell, effective T cell, and T regulatory (T reg) cell (Fig.
S3). Therefore, these data suggest that GSDMD deficiency sup-
presses the priming and differentiation of T cells after the in-
duction of EAE, meanwhile increasing T cell accumulation in
peripheral lymphoid organs during disease.
To further address whether GSDMD functions on themyeloid
cells to regulate T cell responses, we next investigated the
composition of myeloid cells in the spleen during EAE. FACS
revealed a marked reduction in the percentages and absolute
numbers of macrophages (CD11b+F4/80+), neutrophils
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Figure 3. GSDMD deletion in peripheral cells attenuates the development of EAE. (A) Immunoblot analysis of the protein expression of GSDMD in
different tissues (heart, liver, kidney, lung, mesenteric LNs [mLN], spleen, small intestine, colon, cortex, midbrain and cerebellum) from WT mice. (B) Im-
munoblot analysis of the protein expression of GSDMD in peripheral cells (BMDMs, bone marrow–derived DCs [BMDCs], and T cells) and CNS resident cells
(microglia, astrocyte, oligodendrocyte progenitor cell [OPC], and neuron) from WT mice. (C) Mean clinical scores after EAE induction and summary graph of
CNS-infiltrating immune cells at day 18 after immunization in WT and GSDMD−/− mice (n = 6 mice per group) adoptively transferred with WT bone marrow
cells. (D)Mean clinical scores after EAE induction and summary graph of CNS-infiltrating immune cells at day 18 after immunization inWTmice (n = 5 or 6 mice
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(CD11b+Gr-1+), and DCs (CD11c+, including classical DCs [cDCs;
CD11c+B220−], and plasmacytoid DCs [pDCs; CD11c+B220+]) in
the spleen of GSDMD−/− mice during EAE relative to WT mice
(Fig. 5 A). Importantly, the percentages and absolute numbers
of MHCII-expressing cells (CD11b+MHCII+ and CD11c+MHCII+)
in spleen were greatly reduced in EAE GSDMD−/− mice (Fig. 5
A). In addition, GSDMD deficiency did not affect the number of
B and natural killer (NK) cells in the spleen during EAE (Fig. 5
B). Moreover, we didn’t find any differences in the frequency
and numbers of lymphocytic and myeloid cells in bone marrow,
blood, and spleens of GSDMD−/− mice relative to WT controls
under homeostatic conditions (Fig. S4). Thus, all these results
further strengthen the conclusion of a key role for GSDMD in
T cell priming by myeloid cells in the secondary lymphoid or-
gans after EAE.
GSDMD deficiency impairs the expression of genes required
for T cell response in CD11b+ cells and CD4+ T cells of
peripheral lymphoid organs during EAE
It is clear from the above results that peripheral myeloid cell–
intrinsic GSDMD functions in peripheral lymphoid organs to
regulate T cell response during EAE. To further dissect the
mechanistic role of GSDMD in myeloid cells that regulates T cell
responses, we performed RNA sequencing analysis using CD11b+
cells sorted from spleens of WT and GSDMD−/− mice at the onset
stage of EAE. Kyoto Encyclopedia of Genes and Genomes (KEGG)
analysis showed the top pathways down-regulated in GSDMD−/−
CD11b+ cells mainly included Th cell differentiation, antigen
processing and presentation, cell adhesion molecules, and cy-
tokine signaling (Fig. 6 A). Consistently, the heatmap and real-
time PCR analysis displayed significantly decreased expression
in several genes associated with T cell response and migration,
such as Il1b, Ifng, Tnf, Osm, H2-Q10, H2-Ob, Itga6, and Ccl5 in
GSDMD−/− cells (Fig. 6, C and D). To further study the impact of
GSDMD deficiency on T cell responses and determine whether
T cells in GSDMD−/− mice display an alteration in gene expres-
sion during EAE, we also performed RNA sequencing (RNA-seq)
and examined the related genes expression in CD4+ T cells sorted
from spleen. The top down-regulated pathways in GSDMD−/− T cells
after EAE induction were involved with Th cell differentiation,
T cell receptor signaling pathway, and cytokine–chemokine sig-
naling according to KEGG analysis (Fig. 6 B). Several genes associ-
ated with T cell activation and migration, such as Il2, Ifng, Tnf, Cd3e,
Ccl5, Ccl22, Ccr4, Cxcr3, and Cxcr6, were down-regulated inGSDMD−/−
T cells at the onset of EAE as indicated in the heatmap and real-time
PCR analysis (Fig. 6, C and D). Moreover, FACS revealed GSDMD
deficiency greatly impaired the expression of Cxcr6, Ccl5, TNF-α,
and CD3e expression on Th1 and Th17 cells during EAE (Fig. 6, E and
F). Thus, these data further demonstrate that the expression of
genes involved in T cell activation, differentiation, andmigration in
CD11b+ and CD4+ cells of peripheral lymphoid organs during EAE is
significantly impaired by the deficiency of GSDMD.
GSDMD in myeloid cells is required for the activation of CD4+
T cells during EAE
To further test the impact of GSDMD deficiency on T cell
function during EAE, CD4+ T or Th17 cells isolated from spleens
ofWT and GSDMD−/−mice at the time of EAE onset (day 12) were
i.v. transferred to Rag1−/− or C57BL/6 WT recipients (Fig. 7 A).
CD4+ T cells from immunized GSDMD−/− mice failed to induce
passive EAE in Rag1−/− or WT recipients, but CD4+ T cells ob-
tained from WT immunized mice promoted mild EAE (Fig. 7 B).
This indicated that GSDMD deficiency results in functional im-
pairment of T cells during EAE induction. Next, to further in-
vestigate whether GSDMD deficiency affects T cell migration,
we directly transferred CD4+ T cells into the brain ofWTmice by
intracerebroventricular (i.c.v.) injection in order to bypass the
migration of T cells from peripheral to CNS. Again, CD4+ T cells
obtained from immunized GSDMD−/− mice developed lower
levels of EAE pathogenesis compared with immunized WT mice
(Fig. 7 C), suggesting that the critical function of GSDMD may
reside in regulating the activation and/or differentiation of
T cells during EAE.
Given that we have earlier shown that GSDMD in peripheral
myeloid cells is responsible for the neuroinflammation and
pathogenesis of EAE, we next examined if peripheral myeloid
cell–intrinsic GSDMD plays a function in T cell activation during
EAE. To this end, we generatedmyeloid cell conditional GSDMD-KO
mice by crossing the GSDMDfl/fl mice with LysM-Cre mice. Since
these conditional KO mice lack GSDMD expression in myeloid
cells and we have already excluded the effect of GSDMD in
microglia using Cx3cr1-CreERT2 mice (Fig. 3, I and J), the LysM-
Cre mice allowed for direct investigation of the role of GSDMD
in peripheral myeloid cells in T cell activation after EAE in-
duction. Notably, the EAE clinical scores and infiltration of
immune cells into CNS were considerably diminished in
GSDMDfl/flLysM-Cre mice relative to GSDMDfl/fl mice (Fig. 7, D
and E). Moreover, T cell proliferationwas significantly impaired
in the CNS and spleens of GSDMDfl/flLysM-Cremice, as shown by
reduced staining of the proliferation marker CD4+Ki67+ at the
EAE peak stage (Fig. 7, F and G). Additionally, we observed a
significant increase in the number of CD4 T cells in the spleen
per group) adoptively transferred withWT or GSDMD−/− bone marrow cells. (E) Representative plot from flow-cytometric analysis of immune cells infiltrated to
the CNS (spinal cord and brain) of the mice in D. (F) H&E staining and LFB staining of spinal cord sections harvested fromWTmice adoptively transferred with
WT or GSDMD−/− bone marrow cells showing inflammatory cell infiltration and demyelination, respectively (arrows). Scale bar, 200 µm. (G) Quantitative PCR
analysis of the relative mRNA expression of proinflammatory cytokines and chemokines in the spinal cord of WT mice (n = 4 mice per group) adoptively
transferred with WT or GSDMD−/− bone marrow cells at the EAE peak. Data were normalized to a reference gene, Hprt. (H) Mean clinical scores after EAE
induction and summary graph of CNS-infiltrating immune cells at day 18 after immunization in GSDMDfl/flCD4-Cre and littermate control GSDMDfl/fl mice (n = 4
or 5 mice per group). (I) Mean clinical scores after EAE induction and summary graph of CNS-infiltrating immune cells at day 18 after immunization in
GSDMDfl/flCx3cr1-CreERT2 and Cx3cr1-CreERT2 mice (n = 4 or 5 mice per group). (J) Immunoblot analysis of GSDMD expression in T cells from indicated mice,
and in microglia and BMDMs from indicated mice at 6 wk after administration of tamoxifen. Data are pooled from three independent experiments. *, P < 0.05;
**, P < 0.01; ***, P < 0.001. Error bars show means ± SEM. Unpaired t test for C, D, H, and I, and multiple unpaired t test for C, D, and G–I.
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and DLNs of GSDMDf/f LysM-Cre mice during EAE relative to
littermate controls (Fig. 7 H), but a marked reduction in the
percentages of Th1 and Th17 cells (Fig. 8, A and B). Moreover,
the number of naive CD62+CD44−CD4+(Th0) T cells in spleen
and LNs was much higher in GSDMDf/f LysM-Cre mice after EAE
than tissues from controls (Fig. 8, A and C). In addition, the
percentages and numbers of macrophages, neutrophils, DCs,
and MHCII-expressing cells were greatly reduced in the spleen
of GSDMDf/f LysM-Cre mice during EAE (Fig. 8, D and E). We
didn’t find any differences in the frequency and numbers of
lymphocytic and myeloid cells in bone marrow, blood, and
spleens of GSDMDf/f LysM-Cre mice relative to littermate con-
trols (Fig. S5). Furthermore, GSDMD deficiency in myeloid cells
did not affect the number of B and NK cells in the spleen during
EAE (Fig. 8 F). Thus, all of these data strongly suggest that
GSDMD in peripheral myeloid cells is essential for T cell acti-
vation and ensuing pathogenesis in EAE. To further exclude an
effect of GSDMD deficiency in microglia, we next performed
adoptive transfer studies in GSDMDf/f LysM-Cre mice and their
littermate controls by adoptive transfer of Th17 cells from im-
munized WT mice. We found that MOG-reactive Th17 cells in-
duced comparable EAE clinical scores between GSDMDf/f LysM-
Cre mice and controls (Fig. 8 G), which further suggests that
GSDMD in peripheral myeloid cells but not in CNS resident
microglia is essential for pathogenesis in EAE.
Pharmacological inhibition of GSDMD attenuates EAE, and
inflammasome-related cytokines promote EAE pathogenesis
in GSDMD-deficient mice
Given that GSDMD-deficient mice show impaired pathogenesis,
we were keen to assess if pharmacological inhibition of GSDMD
could phenocopy the genetic models. We thus directly assessed
the effects of pyroptosis inhibition on EAE progression in vivo
by i.p. administration with disulfiram, a recently described
potent inhibitor of GSDMD (Hu et al., 2018). We found that
disulfiram treatment protected against EAE development and
greatly attenuated the clinical and histopathological scores
(Fig. 9, A–C). Thus, this result further indicates an important
role of GSDMD in the pathogenesis of EAE and suggests a po-
tential therapeutic use of targeting GSDMD-mediated pyroptosis
in MS treatment. Different reports have shown that IL-1β and
IL-18, the downstream cytokines of inflammasome activation,
have high-level expression in MS patients and promote T cell
differentiation, survival, and migration during EAE (Lalor et al.,
2011; Inoue et al., 2012; Martin et al., 2016). Moreover, GSDMD
can facilitate the secretion of IL-1β and IL-18 through cell lysis by
pyroptosis or forming pores in living cells (Shi et al., 2015;
Evavold et al., 2018). To understand whether the impairment of
EAE pathogenesis in GSDMD-deficient mice is completely de-
pendent on the loss of inflammasome-related cytokines, we as-
sessed the effects of IL-1β and IL-18 on EAE progression in vivo
by i.v. administration of their recombinant proteins in WT and
GSDMD−/− mice immunized with MOG. Although administration
of recombinant IL-1β (rIL-1β) and rIL-18 in GSDMD−/− mice de-
veloped more severe EAE as demonstrated by higher clinical and
histopathological scores compared with their PBS-control mice,
the disease severity of GSDMD−/− mice still was milder thanWTs
even after administration with rIL-1β and rIL-18 (Fig. 9, D–F). It
is hardly surprising that this exogenous supplementation ex-
acerbates pathology in WTs since the exogenous levels of these
cytokines likely greatly exceed the endogenous levels under
conditions of EAE, and maximal pathogenesis is limited by the
endogenous levels of IL-1β and IL-18. Importantly, the exacer-
bation of EAE severity by these cytokines in GSDMD KO mice
did not completely reach the severity observed in WT PBS
control mice. Thus, these results indicate that administration of
IL-1β and IL-18 can only partially rescue the impairment of EAE
pathogenesis in GSDMD−/− mice, which suggests that the path-
ogenic role of GSDMD may also be dependent on the release of
other factors in response to the pyroptotic actions of GSDMD.
Discussion
GSDMD protein, a newly identified pyroptosis executioner
downstream of inflammasome activation, has been reported to
accumulate in the CNS ofMS (McKenzie et al., 2018), but it is not
clear what the physiological role andmechanism of GSDMD is in
the EAE pathogenesis. In this study, we found that the ablation
of GSDMD in peripheral myeloid cells reduced the infiltration of
immune cells into the CNS and conferred robust protection from
EAE development in mice immunized with MOG35-55. In addi-
tion, GSDMD deficiency impaired the activation and differenti-
ation of T cell in the secondary lymphoid organs, thus preventing
T cell–mediated neuroinflammation in EAE.
While the recent study suggested GSDMD-mediated py-
roptosis appeared in the CNS of patients with MS and in EAE
mice (McKenzie et al., 2018), the issues of the relative contri-
bution of peripheral versus CNS GSDMD to disease pathology
were unknown. The conclusion that GSDMD-mediated py-
roptosis involves microglia during EAE progression cannot be
addressed only by GSDMD immunoreactivity in Iba-1 immuno-
positive cells in that study because of Iba-1 expression in both
Figure 4. The differentiation and egress of T cells in peripheral lymphoid organs during EAE are impaired in GSDMD−/− mice. (A and B) Spleens and
DLNs harvested from three pairs of WTs and GSDMD−/− mice at day 18 after EAE induction (A) and quantified spleen (SP) weights (n = 5 mice per group; B).
(C) Quantified absolute cell numbers of CD4+ T cells in spleen and DLNs from WTs and GSDMD−/− mice at day 18 after EAE induction (n = 6 mice per group).
(D–F) Flow-cytometric analysis of Th1 (IFN-γ+) and Th17 (IL-17A+) cells from CD4+ T cells in the spleen and DLNs of WT and GSDMD−/− mice (n = 6 mice per
group) at day 18 after EAE induction, and effective T cell (CD44+CD62L−) and naive T cell (CD44−CD62L+) cells from CD4+ T cells in the spleen and DLNs of WT
and GSDMD−/− mice (n = 4 mice per group) at day 18 after EAE induction. Data are presented as a representative plot (D), and quantified percentages and
absolute cell numbers (E and F). (G–I) Flow-cytometric analysis of CFSE-labeled cells, Th1 (IFN-γ+) cells, and Th17 (IL-17A+) cells from CD4+ T cells at day 5 after
in vitro cocultured with DCs (n = 3 per group). Data are presented as a representative plot (G and H) and quantified percentages (I). Data are pooled from three
independent experiments (A–E) or from two independent experiments (F–I). *, P < 0.05; **, P < 0.01; ***, P < 0.001. Error bars show means ± SEM. Unpaired
t test for B, C, and I, and multiple unpaired t test for E, F, and I. CTRL, control; max, maximum.
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Figure 5. Myeloid cells in peripheral lymphoid organs during EAE are impaired in GSDMD−/− mice. (A) Flow-cytometric analysis of macrophages
(Ma; CD11b+F4/80+), neutrophils (Neu; CD11b+Gr-1+), DCs (CD11c+, including cDCs [CD11c+B220−] and pDCs [CD11c+B220+]), and MHCII-expressing cells
(CD11b+MHCII+ and CD11c+MHCII+) in the spleen (SP) of WT and GSDMD−/− mice (n = 4 mice per group) at day 18 after EAE induction. Data are presented as a
representative plot, quantified percentages, and absolute cell numbers. (B) Flow-cytometric analysis of NK cells (NK1.1+) and B cells (CD19+) in the spleen of
WT and GSDMD−/− mice (n = 4 mice per group) at day 18 after EAE induction. Data are presented as a representative plot, quantified percentages, and absolute
cell numbers. Data are pooled from two independent experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001. Error bars show means ± SEM. Multiple unpaired
t test for A and B. SSC-A, side scatter–area.
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Figure 6. GSDMD deficiency attenuates the expression of genes required for T cell response in CD11b+ cell and CD4+ T cell of peripheral lymphoid
organs during EAE. (A and B) KEGG analysis shows the most significantly enriched signaling pathways in CD11b+ macrophages (A) and CD4+ T cells (B) sorted
from spleens of WT and GSDMD−/− mice at day 12 after EAE induction. (C) The heatmaps of genes with adjusted P value <0.05, false discovery rate <0.05, and
log2 fold-change >1.2 from RNA-seq analysis of CD11b+ myeloid cells and CD4+ T cells isolated from spleens of three pairs ofWTs and GSDMD−/−mice at day 12
after EAE induction. (D) Quantitative PCR analysis of the indicated genes in CD11b+ myeloid cells and CD4+ T cells sorted from spleens in C (n = 3 mice per
group). Data were normalized to a reference gene, Hprt. (E and F) Flow-cytometric analysis of CD3e+, Cxcr6+, TNFα+, and Ccl5+ cells from Th1 and Th17 cells in
the spleen of WT and GSDMD−/− mice (n = 4 mice per group) at day 18 after EAE induction. Data are presented as a representative plot (E) and quantified
percentages (F). Data are pooled from three independent experiments (E and F). *, P < 0.05; **, P < 0.01; ***, P < 0.001. Error bars show means ± SEM. Two-
way ANOVA with Sidak’s multiple comparisons test for D. Multiple unpaired t test for F.
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Figure 7. GSDMD in peripheral myeloid cells is essential for the activation of CD4+ T Cells during EAE. (A) Schematic representation of the experiments
in B, C, and Fig. 8 G. CD4+ T cells were obtained from spleens of WT or GSDMD−/− mice at day 12 after EAE induction, then transferred into Rag1−/− mice by i.v.
injection or into WT mice by i.c.v. injection. DLN cells were obtained from WT or GSDMD−/− mice at day 12 after EAE induction, then cultured in vitro with
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peripheral and CNS macrophages (Müller et al., 2015). In fact,
both peripheral and CNS macrophages contribute to EAE pro-
gression (Bauer et al., 1995; Xiao et al., 2013; Duffy et al., 2014).
Here we found that GSDMD in peripheral cells is indispensable
for EAE induction by using the bone marrow chimeric EAE
models in which the bonemarrow from GSDMD−/− mice exhibits
impaired capability to induce neuroinflammation and patho-
genesis of EAE. Moreover, GSDMD-specific deletion in microglia
by using the GSDMDfl/fl Cx3cr1-CreERT2 mice does not suppress
CNS autoimmune inflammation after EAE induction, suggesting
that GSDMD inmicroglia does not play a major role in regulating
EAE pathogenesis. Notably, we observed an abundance of
GSDMD immunoreactivity near the areas surrounding blood
vessels of spinal cords within EAE, indicating that peripheral
cells might be recruited and undergo pyroptosis in the diseased
brain. Additionally, the studies in GSDMDf/f LysM-Cre mice also
showed that GSDMD deficiency in myeloid cells attenuated the
progression of EAE. Therefore, our studies provide the first
demonstration of a peripheral myeloid–intrinsic role for GSDMD
in driving neuroinflammation in EAE.
Our RNA-seq analysis revealed that the major immune
pathways down-regulated in CD11b+ cells from immunized
GSDMD−/− mice were associated with T cell response, including
Th1 and Th17 cell differentiation, antigen processing and pre-
sentation, cell adhesion molecules, and cytokine signaling,
which indicated that GSDMD-sufficient APCs are essential for
priming T cell immune response. The heatmap results summa-
rized that GSDMD deficiency severely impaired the expression
of several genes for T cell activation and differentiation, such as
Tnf, Ifng, Il1b, H2-Q10, and H2-Ob. TNF-α, IFN-γ, and IL-1β are
key pro-inflammatory cytokines for the expansion and differ-
entiation of reactive T cells in the secondary lymphoid organs,
and an abundance of previously published reports demonstrated
their critical roles in EAE development (Hirota et al., 2011;
Raphael et al., 2015). H2-Q10 and H2-Ob are certain MHC
haplotypes, and the importance of specific MHC molecules in
determining EAE susceptibility has been well established
(Weissert et al., 1998; Irla et al., 2010). In addition, the signifi-
cantly reduced expression of genes for chemotaxis and adhesion,
including Ccl5, Ccr4, Ccr6, and Itga6, was observed in splenic
CD11b+ cells from immunized GSDMD−/−mice. There have been a
number of reports that chemotaxis molecules that enhance im-
mune cell migration are strongly connected with EAE progres-
sion (Inoue et al., 2012; Poppensieker et al., 2012; Cheng and
Chen, 2014). For CD4+ T cell from EAE mice, KEGG pathway
analysis showed that the biological terms down-regulated in
GSDMD−/− cells majorly include Th1 and Th17 cell differentia-
tion, T cell signaling pathway, cell adhesion molecules, and
cytokine–chemokine signaling. Significant reductions in mRNA
levels of Il2, Ifng, Tnf, Cd3e, Ccl5, Ccl22, Ccr4, Cxcr3, and Cxcr6were
identified in splenic CD4+ T cells from GSDMD−/− mice. IL-2 and
CD3e are necessary for the expansion and survive of reactive
T cells (Tamura and Nariuchi, 1992; Liao et al., 2013). TNF-α and
IFN-γ can drive and amplify T cell response and inflammation
during EAE pathogenesis (Raphael et al., 2015). Ccl5, Ccl22, Ccr4,
Cxcr3, and Cxcr6 are migration-related molecules, which are
required for T cells to enhance their migration ability to the CNS
during the development of EAE (dos Santos et al., 2005; Inoue
et al., 2012). Therefore, GSDMD-mediated pyroptosis up-
regulates the expression of genes required for T cell response
in the secondary lymphoid organs, which are involved in de-
velopment of EAE and probably in MS as well.
Although RNA-seq results indicated that GSDMD deficiency
might affect T cell migration into CNS, direct injection of CD4+
T cell from immunized GSDMD−/− mice injection into the CNS
induced much milder EAE compared with that induced by WT
CD4+ T cells, suggesting that T cell activation is likely to be the
substantive pathway affected by GSDMD deficiency during EAE.
Consistent with this, our studies in GSDMDf/f LysM-Cre mice
further showed that the protective effect of GSDMD deficiency
in myeloid cells was associated with the attenuation of T cell
activation and proliferation during EAE. We demonstrate that
the administration of IL-1β and IL-18 only partially rescued the
impairment of EAE pathogenesis in GSDMD−/− mice. Notably, a
recent study showed that GSDMD deficiency promotes cyclic
GMP-AMP synthase–dependent IFN production by reducing
intracellular potassium (K+) efflux through GSDMD-formed
pores (Banerjee et al., 2018). IFN-β administration is a first-
line disease-modifying therapy for MS and thought to control
CNS inflammation and neurodegeneration (Banerjee et al.,
2018). Thus, whether the effects of GSDMD on IFN production
are involved in GSDMD-mediated EAE progression needs to be
further investigated in the future.
In summary, our study is the first to report the physiological
role of GSDMD as a key mediator in autoimmune inflammation
and pathogenesis during EAE. We propose a model in which
peripheral myeloid cell–intrinsic GSDMDmediates pyroptosis to
instigate inflammation and promote the activation and differ-
entiation of T cells in the secondary lymphoid organs, thus
driving T cell–mediated neuroinflammation and demyelination
in the CNS of EAE (Fig. 10). The development of therapeutic
strategies to specifically target GSDMD-mediated pyroptosis
MOG35-55 and IL-23 under Th17 cell–polarizing conditions before transfer into sublethal irradiatedWTs or GSDMDfl/fl and GSDMDfl/flLysM-Cre mice, respectively.
(B and C)Mean clinical scores after CD4 T cell and Th17 cell transfer by i.v. (B) and CD4 T cell transfer by i.c.v. (C; n = 5mice per group). (D)Mean clinical scores
after EAE induction in GSDMDfl/flLysM-Cre and littermate control GSDMDfl/fl mice (n = 5 mice per group); immunoblot analysis of GSDMD expression in BMDMs
from indicated mice. (E) Summary graph of CNS-infiltrating immune cells at day 18 after immunization in GSDMDfl/flLysM-Cre and littermate GSDMDfl/fl mice
(n = 5 mice per group). (F) Flow-cytometric analysis of KI67+ cells among CD4+ T cells in the CNS and spleens (SP) of GSDMDfl/flLysM-Cre and littermate
GSDMDfl/fl mice at day 18 after immunization (n = 5 mice per group). (G) Immunofluorescent labeling of CD3 (red) and KI67 (green) demonstrate the pro-
liferation of T cells in the spinal cord of indicated mice at day 18 after immunization. Data are presented as a representative image (left) and quantified
percentage (right). Scale bar, 50 µm. (H) Quantified absolute cell numbers of CD4+ T cell in spleen and DLNs from GSDMDfl/flLysM-Cre and littermate control
GSDMDfl/fl mice at day 18 after EAE induction (n = 4 mice per group). Data are pooled from three independent experiments (A–G) or from two independent
experiments (H). *, P < 0.05; **, P < 0.01; ***, P < 0.001. Error bars show means ± SEM. Unpaired t test for B–D and F–H, and multiple unpaired t test for E.
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might be useful for the inhibition of CNS inflammation and
MS treatment.
Materials and methods
Mice
Female mice with the C57BL/6 background were used in this
study. The Gsdmd−/− mice were kindly provided by Dr. Feng
Shao (National Institute of Biological Sciences, Beijing, China).
The Gsdmdflox/flox mice was generated using conditional gene
targeting methods by Cyagen Biosciences. To generate this
mouse, the strategy of gene targeting and construction of the
conditional targeting vector were established to delete the exon
3 genomic region of Gsdmd gene by flanking loxP sites and a Neo
cassette. C57BL/6 mouse embryonic stem (ES) cells were elec-
troporated with linearized Gsdmd targeting vector, and screen-
ing of the G418 resistant colonies was performed according to
routine protocol. The homologous recombined ES cell clones
were identified by PCR and confirmed by Southern blot analysis.
The Neo selection cassette on the targeting construct was ca-
pable of removing itself after ES cell targeting without the need
to breed to Flp deleter mice by the TetraOne ES Cell technique.
Tail DNAs were genotyped using the primer sets specific to the
floxed regions of Gsdmdflox/+ mice. Primers for 59 floxed allele
were as follows: primers P1 (59-GGACCCTGAGAGAAAGACATA
CCCAT-39) and P2 (59-GTTGGGATGTTGGGATGGAACTCC-39);
WT mice results in generation of a 148-bp fragment with a 261-
bp fragment corresponding to the floxed allele–positive mice.
Primers for 39 floxed allele were as follows: primers P3 (59-CTC
TACTCCTCTGGTCCTATTTCC-39) and P4 (59- CACAGCACTACG
TTCCATCGGT-39). The 364-bp fragment for the WT allele and
the 420-bp fragment for the floxed allele were reconfirmed for
heterozygous Gsdmd flox/+ mice. Gsdmd floxed mice were crossed
with lysozymeM-Cremice (LysM-Cre; The Jackson Laboratory) to
generate myeloid cell–conditional Gsdmd KO mice (Gsdmdflox/flox
LysM-Cre) or with CD4-Cre mice (The Jackson Laboratory) to
produce T cell–conditional Gsdmd KO mice (Gsdmdflox/flox CD4-
Cre). For the microglia-conditional Gsdmd KO mice, we crossed
Gsdmd floxedmicewith Cx3cr1-CreERT2-EYFPmice (The Jackson
Laboratory) to generate Gsdmdflox/flox Cx3cr1-CreERT2-EYFP
mice, and then the mice were i.p injected with 3 mg tamoxifen
(T5648; Sigma-Aldrich) dissolved in 200 µl corn oil (C8267;
Sigma-Aldrich) for 5 d consecutively to induce the expression of
Cre recombinase. After 6 wk, the tamoxifen-induced mice were
microglia–conditional Gsdmd KO mice and used for the EAE
study. All mice were kept in a barrier facility, and all animal
experiments were conducted in accordance with the procedure
approved by the Ethical Review Committee for Laboratory An-
imal Welfare of Nanjing Medical University.
Antibodies and reagents
Antibodies to GSDMD (ab219800, ab209845) and CD31
(ab24590) were from Abcam. Anti–caspase-11 (17D9, C1354),
anti–α-tubulin (T9026), anti–β-actin (A1978), and anti-GFAP
(G3893) were from Sigma-Aldrich. Anti–caspase-11 (NB120-
10454) was from Novus. Anti–caspase-1 (AG-20B-0042-C100)
was from Adipogen. Anti-Iba1 (019–19741) was fromWako. Anti-
CD45-FITC (30-F11,11-0451-82), anti-CD8a-PE (53–6.7,12-0081-
83), anti-CD11b-APC (M1/70,17-0112-82), anti-CD11b-FITC (M1/
70,11-0112-82), anti-F4/80-APC (BM8,17-4801-82), anti-Gr-1-
PerCP-Cyanine5.5 (RB6-8C5,45-5931-80), anti-CD11c-PE
(N418,12-0114-81), anti-B220-PerCP-Cyanine5.5 (RA3-6B2,5-
0452-80), anti-NK1.1-PE-Cyanine7 (PKB6,25-5941-82), anti-IL17-
PE (eBio18B7,12-7177-81), anti-IFN-γ-PerCP-Cyanine5.5
(XMG1.2,85-45-7311-82), anti-Hu/MoCD44-FITC (IM7,11-0441-
82), anti-Foxp3-APC (FJK-16s,17-5773-80A), anti-CD62L-APC
(MEL-14,17-0621-82), anti-CD25-PE (PC61.5,12-0251-81B),
anti-CD19-APC (eBio1D3,17-0193-82), and anti-CD3e-FITC
(145-2C11,11-0031-81) were from eBioscience. Anti-CD4-APC-
Cy7(GK1.5,100414), anti-Ki-67-PE (11F6,151209), anti-Cxcr6-Briliant
Violet 421 (SA051D1,151109), anti-TNF-α-PE (MP6-XT22,506306),
and anti-CCL5-PE (2E9/CCL5,149104) were from BioLegend. FAM-
FLICA Caspase-1 Assay Kit (98) was from ImmunoChemistry.
Anti-IL4 (11B11, 16–7041-85), anti–IFN-γ (RA-6A2,16-7312-85),
anti-IL12/IL23p40 (C17.8,16-7123-81), mouse IL-6 recombi-
nant protein (14–8061-62), mouse IL-12 p70 recombinant
protein (14–8121-62), and mouse TGF β 1 recombinant protein
(14–8342-62) were from Invitrogen. Pertussis toxin (180) was
from List Biological Laboratories.Mycobaterium tuberculosisH37Ra
(231141) was from BD. Incomplete Freund’s adjuvant (F5506) was
from Sigma-Aldrich. MOG35-55 peptide (residues 35–55, Met-
Glu-Val-Gly-Trp-Tyr-Arg-Ser-Pro-Phe-Ser-Arg-Val-Val-His-Leu-
Tyr-Arg-Asn-Gly-Lys) was synthesized by Sangon Biotech.
Induction and assessment of EAE
To induce EAE, MOG35-55 peptide (200 μg per mouse) was
emulsified with CFA (50 μl per mouse, including 4 mg/ml M.
tuberculosis H37Ra) and 50 μl incomplete Freund’s adjuvant.
Pertussis toxin (250 ng permouse) was applied intravenously on
days 0 and 2 after immunization. Mice were assessed daily for
Figure 8. GSDMD in peripheral myeloid cells is essential for T cell priming by myeloid cells during EAE. (A–C) Flow-cytometric analysis of Th1 (IFN-γ+)
and Th17 (IL-17A+) cells, effective T cells (CD44+CD62L−), and naive T cells (CD44−CD62L+) from CD4+ T cells in the spleen (SP) and DLNs of GSDMDfl/flLysM-Cre
and littermate control GSDMDfl/fl mice (n = 4 mice per group) at day 18 after EAE induction. Data are presented as a representative plot (A), and quantified
percentages and absolute cell numbers (B and C). (D and E) Flow-cytometric analysis of macrophages (Ma; CD11b+F4/80+), neutrophils (Neu; CD11b+Gr-1+),
DCs (CD11c+, including cDCs [CD11c+B220−] and pDCs [CD11c+B220+]), and MHCII-expressing cells (CD11b+MHCII+ and CD11c+MHCII+) in the spleen of
GSDMDfl/flLysM-Cre and littermate control GSDMDfl/fl mice (n = 4 mice per group) at day 18 after EAE induction. Data are presented as a representative plot (D),
and quantified percentages and absolute cell numbers (D and E). (F) Flow-cytometric analysis of NK cells (NK1.1+) and B cells (CD19+) in the spleen of GSDMDfl/fl
and GSDMDfl/flLysM-Cre mice (n = 4 mice per group) at day 18 after EAE induction. Data are presented as a representative plot, quantified percentages and
absolute cell numbers. (G) Mean clinical scores after Th17-cell transferring by i.v. to indicated mice (n = 5 mice per group). Data are pooled from two in-
dependent experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001. Error bars showmeans ± SEM. Unpaired t test for G and multiple unpaired t test for B, C, E, and
F. SSC-A, side scatter–area.
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Figure 9. Pharmacological inhibition of GSDMD attenuates EAE, and inflammasome-related cytokines promote EAE pathogenesis in GSDMD-
deficient mice. (A) Mean clinical scores of WT mice injected (i.p.) with disulfiram or PBS daily after EAE induction, respectively (n = 5 mice per group).
(B and C) Representative images (B) and histological scores (C) of H&E staining and LFB staining of spinal cord sections from mice in A. Inflammatory cell
infiltration and demyelination indicated by arrow. Scale bar, 200 µm. (D) Mean clinical scores of WTs and GSDMD−/− mice which were i.v. injected with rIL-
1β and rIL-18 combination or PBS at day 4, 8, 12, and 16 after EAE induction, respectively (n = 5 mice per group). (E and F) Representative images (E) and
histological scores (F) of H&E staining and LFB staining of spinal cord sections from mice in D. Inflammatory cell infiltration and demyelination indicated by
arrow. Scale bars, 200 µm. Histological scores in C and F: 0, no inflammatory cell infiltration and no demyelination; 1, slight inflammatory cell infiltration or
demyelination observed; 2, moderate inflammatory cell infiltration or demyelination in several spots; 3, substantial inflammatory cell infiltration and large area
of demyelination. Data are pooled from three independent experiments (D–F) or from two independent experiments (A–C). *, P < 0.05; **, P < 0.01. Error bars
show means ± SEM. Unpaired t test for A, C, D, and F.
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clinical signs of EAE in a blinded fashion. EAE score was eval-
uated as follows: 0.5, partial tail paralysis; 1, tail paralysis; 1.5,
reversible corrective reflex impairment; 2, corrective reflex
impairment; 2.5, one hindlimb paralysis; 3, both hindlimbs pa-
ralysis; 3.5, both hindlimbs paralysis and one forelimb paralysis;
4, hindlimb and forelimb paralysis; and 5, death.
Bone marrow chimeras
The recipient mice were subjected to lethal-dose irradiation (10
Gy), and 1 d later, bone marrow cells (10 × 106) derived from the
tibiae and femurs of donor mice were i.v. injected into lethally
irradiated mice. Lethal dose irradiation can eliminate bone
marrow and peripheral immune cells without affecting the
radiation-resistant CNS resident cells in the recipient mice, so
the peripheral immune system of chimeric mice will be re-
constructed by bone marrow cells from donor mice. After 8 wk,
the chimeric mice were then subjected to EAE induction.
Adoptive transfer of CD4+ T cells and Th17 cells
CD4+ T cells were isolated from spleens of WT and GSDMD−/−
mice at 12 d after EAE induction by using CD4 negative selection
MicroBeads (Stem Cell). Isolated T cells were adoptively trans-
ferred by i.v. injection (3 × 106) to RAG-1 mice or i.c.v. injection
(2 × 106) to WT mice. Mice were also i.v. injected with pertussis
toxin on days 0 and 2 after transfer. Polarized Th17 cells were
also used to induce passive EAE. We first collected DLN cells
from WT and GSDMD−/− donor mice at 12 d after MOG35-55 im-
munization, and cultured cells for 5 d with MOG35-55 (25 µg/ml)
and IL-23 (20 ng/ml) under Th17 cell polarizing conditions. The
MOG35-55-specific polarized Th17 cells were then adoptively
transferred by i.v. injection (3 × 107) to sublethal irradiated
(5 Gy) WT recipient mice or GSDMDfl/fl and GSDMDfl/flLysM-
Cre mice.
In vitro T cell proliferation and Th1/Th17 cell polarization
CD4+ T cells were isolated from DLNs of WT mice at 12 d after
EAE induction by CD4 negative selection MicroBeads (Stem
Cell). The isolated T cells (1 × 106) were cocultured with WT or
GSDMD−/− DCs (2 × 105) that were pretreated with LPS (1 µg/ml)
for 4 h and washed twice before co-culture. For proliferation
experiments, T cells were labeled with 5 µM CFSE and co-
cultured with DCs in the presence of MOG35-55 (3 µg/ml). For
polarization experiments, T cells were cocultured with DCs in
the presence of MOG35-55 (3 µg/ml) under Th1 cell polarizing
conditions (anti–IL-4, 10 µg/ml; IL-12, 10 ng/ml) or Th17 cell
polarizing conditions (anti–IL-4, 10 µg/ml; anti–IL-12, 10 µg/ml;
anti–IFN-γ, 10 µg/ml; IL-6, 50 ng/ml; and TGF-β, 5 ng/ml). CFSE
dilution and Th1/Th17-cell percentages were determined by
FACS at 5 d after co-culture.
Histological and immunohistochemistry
All spinal cord tissue sections used here were 5 µm thick. For
paraffin-embedded tissue, spinal cords collected from PBS-
perfused mice were fixed in 4% paraformaldehyde overnight.
Sections were stained with H&E or with LFB for evaluation of
inflammation and demyelination, respectively. For immuno-
histochemical staining, sections were blocked and incubated
with primary antibodies and horseradish peroxidase-conjugated
Figure 10. Model for GSDMD function in EAE pathogenesis. During EAE development, peripheral myeloid cell–intrinsic GSDMD mediates pyroptosis to
instigate inflammation and promote the activation and differentiation of T cells in the secondary lymphoid organs, thus driving T cell–mediated neuro-
inflammation and demyelination in the CNS of EAE.
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secondary antibodies after heat-induced antigen retrieval. Dia-
minobenzidine was used for detection. Images were captured
with a Nikon 50i microscope.
Immunofluorescence staining
Tissue sections were incubated at 4°C overnight with primary
antibodies to IBA1, GFAP, MBP, and CD4. Slides were then in-
cubated with indicated secondary antibodies. The nuclei were
counterstained with DAPI (Sigma-Aldrich). Slides were dried
and mounted using ProLong Antifade mounting medium (Be-
yotime Biotechnology). Slides were visualized using a Nikon 50i
fluorescent microscope.
Flow cytometry
For preparation of immune cells in the CNS, brains, and spinal
cords from MOG35–55-immunized mice were excised and di-
gested at 37°C with collagenase type IV (0.5 mg/ml; Sigma-Al-
drich) and DNase I (10 U/ml; Roche) in RPMI 1640 under
agitation (200 rpm) conditions for 60 min. The digested tissues
were filtered through a 100-µm filter, and the plunger end of the
syringe was used to push the cells over the filter. Homogeneous
cell suspensions were centrifuged over the Percoll density gra-
dient (GE Healthcare) and separated by collecting the interface
fractions between 37% and 70% Percoll. Mononuclear cells were
isolated from the interface. The cells were suspended in PBS
containing 2% (wt/vol) FBS. After intensive washing, cells were
stained with fluorochrome-conjugated surface marker anti-
bodies for FACS analysis. The following antibodies were used:
CD45, CD4, CD8, and CD11b. For intracellular cytokine staining,
cells were stimulated with phorbol 12-myristate 13-acetate
(Multi Sciences), ionomycin (Multi Sciences), and brefeldin A
(Invitrogen) for the 4 h of culture. Cells were fixed and per-
meabilized with the Intracelluar Fixation & Permeabilization
Buffer Set (eBioscience) and then subjected to cytokine staining
flow cytometry analyses. All flow cytometry was performed on
an Attune NxT flow cytometer (Thermo Fisher Scientific), and
data were analyzed by FlowJo 7.6.1 software.
Quantitative RT-PCR
Total RNA was extracted by using TRIzol reagent (Life) and
subjected to cDNA synthesis. Quantitative RT-PCR was per-
formed using SYBR Green Supermix (Vazyme). The expression
of a single gene was calculated by a standard curve method and
standardized to the expression of Hprt.
The following primers were used: Ccl22 S As, 59-TCGGTTCTT
GACGGTTAT-39 and 59-TGCTGCCAGGACTACATC-39; Ccl5 S As,
59-GACACCACTCCCTGCTGCTT-39 and 59-ACACTTGGCGGTTCC
TTCG-39; Ccr4 S As, 59-TCCAAACAGACCCAACAA-39 and 59-ACC
ACCCAGGATGAAACT-39; Ccr6 S As, 59-TCACGACTCGGATTG
CTC-39 and 59-CTGCTGGGTATGGGACTG-39; Cxcr3 S As, 59-GTT
GGCTGATAGGTAGATGAA-39 and 59-CTGCTGTCCAGTGGGTTT-
39; Cxcr6 S As, 59-CACCCAAATGAGCAAGCAAA-39 and 59-ATG
GATGATGGGCATCAAGAGTCAG-39; Ifnγ S As, 59-CATGAGTAT
TGCCAAGTTTGAGG-39 and 59-CGACTCCTTTTCCGCTTCC-39;
Itga6 S As, 59-GTTCTGTTCGCCCTCTGC-39 59-TGCCTGCTCTAC
CTGTCC-39; Il1b S As, 59-ATGCCACCTTTTGACAGTGATG-39 and
59-GTTGATGTGCTGCTGCGAGA-39; cxcl1 S As, 59-AGCTGCGCT
GTCAGTGCCT-39 and 59-TGTGGCTATGACTTCGGTTTGG-39;
Tnfa S As, 59-TACTGAACTTCGGGGTGATCG-39 and 59-TCCTCC
ACTTGGTGGTTTGC-39; Osm S As, 59-GAGCCATCGTCCCATTCC-
39 and 59-CTCACGGTCCACTACAACAC-39; H2-q10 S As, 59-AGT
ATTGGGAGCGGGAGA-39 and 59-CCGTCGTATGCGTATTGC-39;
H2-ob S As, 59-GACAACAGTAATGCTGGAAATGA-39 and 59-TGA
GCCTTGAGATGGATAACAAC-39; Cd3e S As, 59-TGGAGCAAG
AATAGGAAGGC-39 and 59-GGTTGGGAACAGGTGGTG-39; Il2 S
As, 59-CTCTGCGGCATGTTCTGGA-39 and 59-TCATCATCGAAT
TGGCACTCA-39; Hprt S As, 59-GTCCCAGCGTCGTGATTAGC-39
and 59-TGGCCTCCCATCTCCTTCA-39.
Immunoblot
Spinal cords from MOG35–55-immunized mice were excised and
placed in NP-40 lysis buffer (50 mM Tris-HCl, pH 7.4, con-
taining 150 mM NaCl, 1% [vol/vol] Igepal, 10% [wt/vol] glycerol,
50 mM NaF, 1 mM Na3VO4, 1 mM dithiothreitol, 1 mM phenyl-
methylsulphonyl fluoride, and complete protease inhibitor
“cocktail” [Sigma-Aldrich]), followed by tissue homogenization
and then incubation for 30 min at 4°C. The lysates were
centrifuged for 10 min at 14,000 g for removal of cell debris and
nuclei. Supernatants were assayed for protein concentration,
and lysate samples (50 µg) were resolved by SDS-PAGE, trans-
ferred to nitrocellulose membranes, and analyzed by immuno-
blot with the appropriate antibodies. Immunoreactivity was
visualized by the Odyssey Imaging System (LI-COR Biosciences)
or enhanced chemiluminescence.
RNA-seq analysis
For RNA-seq, CD11b+ and CD4+-T cells were isolated from
spleens of WT and GSDMD−/− mice at 14 d after immunization
by using CD11b and CD4 MicroBeads (Stem Cell), respectively.
RNA isolation, library construction, and sequencing were
performed on a BGISEQ-500 (Beijing Genomic Institution).
Clean reads were mapped to the mouse genome (GRCm38.p5)
by HISAT2. For gene expression analysis, the matched reads
were calculated and then normalized to FPKM. Fold changes
were calculated for all possible comparisons, and a 1.2-fold
cutoff was used to select genes with expression changes.
KEGG pathway analysis was performed using the R package,
using significantly differentially expressed genes (P < 0.05) as
target genes. Raw data files and processed files have been
deposited in the Gene Expression Omnibus under accession
no. GSE126289).
rIL-1β, rIL-18, and disulfiram treatment in EAE mice
rIL-1β (25 ng per mouse; Stem Cell) and rIL-18 (25 ng per mouse;
R&D Systems) were i.v. injected intoWT and GSDMD−/−mice on
days 4, 8, 12, and 16 (where day 0 is MOG35–55 immunization).
Disulfiram (10 mg/kg) was i.p. injected into WT mice daily after
immunization. Clinical signs and histological analysis were
performed as described above.
Statistical analyses
The data were analyzed by GraphPadPrism 7.0 software and are
presented as the mean ± SEM. The statistics were analyzed by
using an unpaired t test for two groups and multiple t test or
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two-way ANOVA for multiple groups. P values were provided as
*, P < 0.05; **, P < 0.01; and ***, P < 0.001.
Data availability
Sequencing data were deposited in the Gene Expression Omni-
bus under accession no. GSE126289.
Online supplemental material
Fig. S1 shows the activation of GSDMD and caspase-11 in DLNs
and spinal cord and that GSDMD deficiency inhibits the acti-
vation of macrophages, microglia, and astrocytes in CNS of EAE
mice. Fig. S2 shows GSDMD conditional KO mice strategy. Fig.
S3 shows that GSDMD deficiency does not affect the develop-
ment of T and B cells. Fig. S4 shows that GSDMD deficiency does
not affect the development of myeloid cells and NK cells. Fig. S5
shows that GSDMD deficiency in myeloid cells does not affect
the development of lymphocytic cells and myeloid cells.
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